Cholera and diarrheal diseases in Cuamba District, Niassa Province, Mozambique: Systematic healthcare facility-based surveillance strengthening, characteristics of suspected cholera and diarrheal patients, and incidence of diarrheal diseases.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Cholera*/epidemiology ; Cholera*/prevention & control ; Diarrhea*/epidemiology ; Diarrhea*/microbiology ; Diarrhea*/prevention & control ; Health Facilities*; Humans ; Mozambique/epidemiology ; Adolescent ; Adult ; Female ; Male ; Child ; Young Adult ; Child, Preschool ; Incidence ; Middle Aged ; Infant ; Prospective Studies ; Disease Outbreaks ; Aged

Background: Mozambique is one of the countries in Africa that is continuously at risk of cholera outbreaks due to poor sanitation, hygiene, and limited access to potable water in some districts. The Mozambique Cholera Prevention and Surveillance (MOCA) project was implemented in Cuamba District, Niassa Province to prevent and control cholera outbreaks through a preemptive cholera vaccination, strengthened surveillance system for cholera and diarrheal diseases, and better understanding of cholera-related healthcare seeking behavior of local populations, which may further guide the national cholera control and prevention strategies. This article presents the surveillance component of the MOCA project.
Methodology/principal Findings: A prospective healthcare facility (HCF)-based surveillance of cholera and diarrheal disease was conducted in six HCFs in the District of Cuamba from March 2019 to December 2020. A systematic surveillance procedure has been put in place with capacity building in selected sentinel HCFs and a basic microbiology laboratory established on-site. Patients presenting with suspected cholera or other diarrheal symptoms were eligible for enrollment. Clinical data and rectal swab samples were collected for laboratory confirmation of Vibrio Cholerae and other pathogens. A total of 419 eligible patients from six HCFs were enrolled. The median age was 19.8 years with a similar age distribution between sentinel sites. The majority were patients who exhibited diarrhea symptoms not suspected of cholera (88.8%; n = 410). Among those, 59.2% (210/397) were female and 59.9% (235/392) were 15 years and above. There were 2 cholera cases, coming outside of the catchment area. The incidence of diarrheal diseases ranged from 40-103 per 100,000 population. No Vibrio cholerae was isolated among surveillance catchment population and Escherichia coli spp. (82/277; 29.6%) was the most common pathogen isolated.
Conclusion/significance: Efforts were made to strengthen the systematic surveillance of suspected cholera with standardised patient screening, enrolment, and diagnostics. The first basic microbiology laboratory in Niassa Province established in Cuamba District under the MOCA project needs to be integrated into the national network of laboratories for sustainability. No reports of laboratory confirmed cholera cases from the surveillance catchment area may be highly related to the pre-emptive oral cholera vaccine (OCV) mass vaccination campaign conducted in 2018 and the use of drugs by local populations prior to visiting the sentinel HCFs. Continued systematic cholera surveillance is needed to closely monitor the cholera endemicity and epidemics, and further evaluate the long-term impact of this vaccination. High incidence of diarrheal illnesses needs to be addressed with improved water, sanitation, and hygiene (WaSH) conditions in Cuamba District. Efforts integrated with the prioritization of prevention measures are fundamental for the control of cholera in the country.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Semá Baltazar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

BMJ Open. 2022 Sep 7;12(9):e053585. (PMID: 36547726)
Int J Infect Dis. 2022 Sep;122:215-221. (PMID: 35605949)
Wkly Epidemiol Rec. 2010 Mar 26;85(13):117-28. (PMID: 20349546)
J Infect Dis. 2018 Oct 15;218(suppl_3):S137-S140. (PMID: 30184102)
Vaccine. 2020 Feb 29;38 Suppl 1:A132-A140. (PMID: 31519444)
Vaccine. 2020 Feb 29;38 Suppl 1:A73-A82. (PMID: 31427135)
Pan Afr Med J. 2022 Aug 15;42:279. (PMID: 36405663)
PLoS Negl Trop Dis. 2017 Oct 9;11(10):e0005941. (PMID: 28991895)
J Infect Dis. 2013 Nov 1;208 Suppl 1:S107-14. (PMID: 24101638)
J R Soc Interface. 2015 Oct 6;12(111):20150703. (PMID: 26423441)
PLoS One. 2016 Jun 03;11(6):e0156674. (PMID: 27258124)
BMJ Glob Health. 2021 Sep;6(9):. (PMID: 34489329)
Int J Environ Res Public Health. 2019 Aug 15;16(16):. (PMID: 31443180)
Curr Top Microbiol Immunol. 2014;379:117-44. (PMID: 24827501)
Infect Dis Poverty. 2020 Jun 16;9(1):68. (PMID: 32546268)
Lancet. 2018 May 12;391(10133):1908-1915. (PMID: 29502905)
BMC Infect Dis. 2019 Apr 15;19(1):322. (PMID: 30987589)
PLoS Negl Trop Dis. 2018 Mar 14;12(3):e0006286. (PMID: 29538377)
J Infect Dis. 2013 Nov 1;208 Suppl 1:S23-31. (PMID: 24101641)
Nutrients. 2022 Mar 10;14(6):. (PMID: 35334821)
Vaccine. 2020 Feb 29;38 Suppl 1:A31-A40. (PMID: 31395455)
J Infect Dev Ctries. 2015 Jul 04;9(6):635-41. (PMID: 26142674)
PLoS One. 2018 Oct 3;13(10):e0198592. (PMID: 30281604)
PLoS Negl Trop Dis. 2015 Jun 04;9(6):e0003832. (PMID: 26043000)

Date Created: 20240430 Date Completed: 20240510 Latest Revision: 20240512

20240512

PMC11086855

10.1371/journal.pntd.0011843

38687808